{"name": "Optimer Pharmaceuticals",
 "permalink": "optimer-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/optimer-pharmaceuticals",
 "homepage_url": "http://www.optimerpharma.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "858.909.0736",
 "description": "",
 "created_at": "Tue Feb 08 04:46:00 UTC 2011",
 "updated_at": "Wed Jan 02 11:14:27 UTC 2013",
 "overview": "\u003Cp\u003EOptimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer\u00e2\u20ac\u2122s development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       61],
      "assets/images/resized/0012/0933/120933v1-max-150x150.png"],
     [[250,
       101],
      "assets/images/resized/0012/0933/120933v1-max-250x250.png"],
     [[263,
       107],
      "assets/images/resized/0012/0933/120933v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Pedro",
      "last_name": "Lichtinger",
      "permalink": "pedro-lichtinger",
      "image": null}},
   {"is_past": false,
    "title": "Chief Scientific Officer \u0026 Senior Vice President, Research and Development",
    "person":
     {"first_name": "Sherwood",
      "last_name": "L. Gorbach",
      "permalink": "sherwood-l-gorbach",
      "image": null}},
   {"is_past": false,
    "title": "Chief Financial Officer \u0026 Senior Vice President, Finance",
    "person":
     {"first_name": "Stephen",
      "last_name": "Webster",
      "permalink": "stephen-webster",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "10110 Sorrento Valley Rd.",
    "address2": "Suite C",
    "zip_code": "92121",
    "city": "San Diego",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Optimer lands $224M licensing pact for promising antibiotic",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 7,
    "source_url": "http://www.fiercebiotech.com/story/optimer-lands-224m-licensing-pact-promising-antibiotic/2011-02-07?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Optimer lands $224M licensing pact for promising antibiotic",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Optimer Pharmaceuticals",
      "permalink": "optimer-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:OPTR"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}